Suppr超能文献

骨质疏松症的预防与治疗:综述

The prevention and treatment of osteoporosis: a review.

作者信息

Cosman Felicia

机构信息

Columbia University College of Physicians and Surgeons, New York, NY, USA.

出版信息

MedGenMed. 2005 May 11;7(2):73.

Abstract

Osteoporosis is a disorder characterized by reduced bone strength, diminished bone density, and altered macrogeometry and microscopic architecture. Adult bone mass is the integral measurement of the bone mass level achieved at the peak minus the rate and duration of subsequent bone loss. There is clearly a genetic predisposition to attained peak bone mass, which occurs by a person's mid-20s. Bone loss with age and menopause are universal, but rates vary among individuals. Both peak bone mass and subsequent bone loss can be modified by environmental factors, such as nutrition, physical activity, and concomitant diseases and medications. Osteoporosis prevention requires adequate calcium and vitamin D intake, regular physical activity, and avoiding smoking and excessive alcohol ingestion. Risk of fracture determines whether medication is also warranted. A previous vertebral or hip fracture is the most important predictor of fracture risk. Bone density is the best predictor of fracture risk for those without prior adult fractures. Age, weight, certain medications, and family history also help establish a person's risk for osteoporotic fractures. All women should have a bone density test by the age of 65 or younger (at the time of menopause) if risk factors are present. Guidelines for men are currently in development. Medications include both antiresorptive and anabolic types. Antiresorptive medications--estrogens, selective estrogen receptor modulators (raloxifene), bisphosphonates (alendronate, risedronate, and ibandronate) and calcitonins--work by reducing rates of bone remodeling. Teriparatide (parathyroid hormone) is the only anabolic agent currently approved for osteoporosis in the United States. It stimulates new bone formation, repairing architectural defects and improving bone density. All persons who have had osteoporotic vertebral or hip fractures and those with a bone mineral density diagnostic of osteoporosis should receive treatment. In those with a bone mineral density above the osteoporosis range, treatment may be indicated depending on the number and severity of other risk factors.

摘要

骨质疏松症是一种以骨强度降低、骨密度减小、宏观几何结构和微观结构改变为特征的病症。成人骨量是达到峰值时的骨量水平减去随后骨丢失的速率和持续时间后的综合测量值。显然,达到峰值骨量存在遗传易感性,峰值骨量在人的25岁左右时出现。随着年龄增长和绝经,骨丢失是普遍现象,但个体之间的速率有所不同。峰值骨量和随后的骨丢失都可受到环境因素的影响,如营养、体育活动以及伴随的疾病和药物。预防骨质疏松症需要摄入足够的钙和维生素D、定期进行体育活动,并避免吸烟和过量饮酒。骨折风险决定是否也需要药物治疗。既往椎体或髋部骨折是骨折风险的最重要预测因素。对于没有成人骨折史的人,骨密度是骨折风险的最佳预测指标。年龄、体重、某些药物和家族史也有助于确定一个人发生骨质疏松性骨折的风险。如果存在危险因素,所有女性在65岁及以下(绝经时)都应进行骨密度检测。目前正在制定男性的指导方针。药物包括抗吸收类和促合成类。抗吸收药物——雌激素、选择性雌激素受体调节剂(雷洛昔芬)、双膦酸盐(阿仑膦酸钠、利塞膦酸钠和伊班膦酸钠)和降钙素——通过降低骨重塑速率发挥作用。特立帕肽(甲状旁腺激素)是目前美国唯一被批准用于治疗骨质疏松症的促合成药物。它刺激新骨形成,修复结构缺陷并提高骨密度。所有发生过骨质疏松性椎体或髋部骨折的人以及骨矿物质密度诊断为骨质疏松症的人都应接受治疗。对于骨矿物质密度高于骨质疏松范围的人,根据其他危险因素的数量和严重程度,可能需要进行治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验